DDW Editor Reece Armstrong speaks to Jeff Glazier, CEO of General Oncology, about the challenges facing pancreatic cancer drug development and the company's activities in the space. RA: Why has pancreatic cancer remained so difficult to treat? JG: Pancreatic cancer is typically diagnosed at an advanced stage, is biologically aggressive, and rapidly develops resistance to therapy. Tumours are highly heterogeneous, both between patients and within the same tumour, […]
To read this content in full, you need to login.
Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!